Postibrutinib relapse outcomes for patients with marginal zone lymphoma.

Although the median postrelapse OS was 38.5 months vs 23.1 months vs 4.3 months in those who received ibrutinib in second-line therapy vs third-line therapy vs fourth-line therapy, respectively, this did not reach statistical significance ( P = .22) ( supplemental Figure 5 ).

also in 111,027 other papers